|
|
|
|
|
|
|
HIGHLIGHTS FROM THE 2024 EUROPEAN ASSOCIATION OF UROLOGY ANNUAL MEETING |
|
|
|
|
|
Plenary Session: Risk-Adapted Screening and Treatment of Screen-Detected Prostate Cancer
|
|
| Risk Adapted Screening for Prostate Cancer in Europe: MRI Only |
| Caroline Moore |
| Caroline Moore presented on risk-adapted screening for prostate cancer in Europe, focusing on the UK ReImagine trial. She highlighted the need to maximize screening benefits while minimizing harm, emphasizing the importance of using advanced tests like MRI. The trial showed that MRI screening resulted in a high rate of clinically significant prostate cancer detection, even among men with low PSA levels, with black men having a significantly lower response rate to screening compared to white men. |
|
|
|
|
|
| Risk Adapted Screening for Prostate Cancer in Europe: PSA Only - the PROBASE German Screening Trial in Young Men |
| Boris Hadaschik, MD |
| Boris Hadaschik presented findings from the German PROBASE screening trial for young men. The trial, ongoing until 2034, involves over 46,000 men receiving baseline PSA screening at ages 45 or 50, with subsequent surveillance based on PSA levels. Among 45-year-old men, only a small number of aggressive prostate cancers were detected (ISUP Grade Group >= 3), indicating a low prevalence. |
|
|
|
|
|
|
Joint Session of the EAU, EANM, ESMO, and ESTRO: A Collaborative Approach - Multidisciplinary Tumor Boards in Stage II Seminoma
|
|
| State-of-the-Art Lecture: Long-Term Toxicity in Testicular Cancer and AYA: Premature Mortality and Morbidity Illustrated |
| Zachary Klaassen, MD, MSc |
| Zachary Klaassen presented on the long-term toxicity of treatment in adolescents and young adults with testicular cancer at the EAU 2024 congress. While cisplatin-based chemotherapy improves survival, it comes with significant adverse health outcomes clusters, including hearing loss, hyperlipidemia, neuropathy, cardiovascular conditions, thyroid disease, and depression/anxiety. |
|
|
|
|
|
|
|
|
|
|
|
Joint Session of the EAU and the CAU
|
|
| Update on PSMA PET/CT: When Does Its Use in Staging Have an Impact on Survival? |
| Wolfgang Fendler, MD |
| Wolfgang Fendler presented an update on PSMA PET/CT's impact on survival, emphasizing its role in prostate cancer stage shifting. While PSMA PET/CT has shown management impact in various settings, including metastatic hormone-sensitive and castration-resistant prostate cancer, evidence regarding its impact on overall survival is still awaited. Ongoing trials, such as PRIMORDIUM and PSMA-SRT, aim to assess the survival benefits of PSMA-guided therapies like salvage radiotherapy, highlighting the need for randomized controlled trial data in this area. |
|
|
|
|
|
|
Progress and Controversies in Oncological Urology: Meeting of the EAU Section of Oncological Urology (ESOU)
|
|
| Options and Challenges in the Management of Oligometastatic Prostate Cancer in the PSMA-PET Era |
| Christopher Sweeney, MBBS |
| Christopher Sweeney presented on managing oligometastatic prostate cancer in the PSMA-PET era at EAU 2024. Challenges include defining oligometastasis and determining optimal treatment. Studies like STOMP and ORIOLE showed benefits of metastasis-directed therapy, especially in eradicating all lesions. Genetic predictors like ATM and BRCA mutations influence treatment response, and combination therapies like ADT + ARSI show promise. |
|
|
|
|
|
| European Urology Oncology Lecture: Survivorship Considerations Across the Spectrum of Genitourinary Oncology |
| Alicia Morgans, MD, MPH |
| Alicia Morgans delivered the European Urology Oncology lecture at EAU 2024, focusing on survivorship considerations in genitourinary oncology. She emphasized that survivorship begins at diagnosis and encompasses a patient's lifetime, distinguishing it from palliative care. Key areas of survivorship care include preventing cancer recurrence, addressing long-term side effects, modifying health behaviors, ensuring care coordination, and managing mental health. |
|
|
|
|
|
|
From Diagnosis to Management: Comprehensive Insights into NMIBC
|
|
| Development of the Bladder Utility Symptom Scale (BUSS Utility): A Novel Tool to Measure Utilities and Quality of Life in Bladder Cancer Patients |
| Girish Kulkarni, MD, Ph.D., FRCPC |
| Girish Kulkarni introduced the Bladder Utility Symptom Scale (BUSS), a tool designed to measure utilities and quality of life in bladder cancer patients. Derived from a 10-item questionnaire, BUSS facilitates the calculation of utilities using two algorithms, one based on bladder cancer patients' responses and another from the general public's responses. This innovative approach enables the assessment of patient preferences and outcomes across various phases of bladder cancer care, aiding in comparative effectiveness research and informing decision-making processes. |
|
|
|
|
|
| Defining Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Comparative Study of EAU and IBCG Criteria |
| Giulio Avesani, MD |
| Giulio Avesani presented a comparative study of EAU and IBCG criteria for intermediate-risk non-muscle invasive bladder cancer. Analyzing 430 NMIBC patients, they found similar recurrence rates at 40 months between the two classifications, but the EAU-defined intermediate-risk group showed a higher risk of progression when receiving adequate BCG treatment compared to the IBCG-defined group. |
|
|
|
|
|
| Towards Defining Follow-up Strategies for Patients with Primary EAU 2021 Intermediate-Risk Non-Muscle Invasive Bladder Cancer |
| Roberto Contieri, MD |
| Roberto Contieri presented a study aimed at defining follow-up strategies for EAU 2021 intermediate-risk non-muscle invasive bladder cancer (NMIBC). They identified two subgroups within the intermediate-risk category: low-risk-of-recurrence and high-risk-of-recurrence based on multifocality and tumor size (>3 cm). |
|
|
|
|
|
| Development and External Validation of an Artificial Intelligence-Based Tool for PROGression Risk Assessment in Non-Muscle Invasive Bladder Cancer: PROGRxN-BCa |
| Jethro Kwong, MD |
| Jethro Kwong presented PROGRxN-BCa, an artificial intelligence-based tool developed to assess the risk of progression in non-muscle invasive bladder cancer (NMIBC) patients. This tool outperformed existing models, achieving a higher c-index and demonstrating better calibration and net benefit across clinically relevant subgroups. PROGRxN-BCa identified patients who may benefit from treatment intensification within the intermediate-risk group, showcasing its potential for personalized treatment strategies |
|
|
|
|
|
|
|
|
|
|
|
